MedTrace Logo

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

NCT03416569 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-08-19

No results posted yet for this study

Summary

To test whether specific aspects of the attention-enhancing effects of nicotine may be mediated by down-stream activation of alpha1 adrenoceptors, the interaction of nicotine and the alpha1 adrenergic antagonist prazosin on cognitive task performance will be tested in human non-smokers. The effects of a low-dose nicotine patch vs. a placebo patch will be tested in the presence and absence of prazosin over 4 test sessions.

Conditions

  • no Condition, Basic Science

Interventions

DRUG

Placebo

placebo skin patch + placebo capsule

DRUG

Nicotine

nicotine patch (7 mg/24 hrs) + placebo capsule

DRUG

Prazosin

placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)

DRUG

Nicotine + Prazosin

nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2019-01-31
Completion
2019-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03416569 on ClinicalTrials.gov